Physiological modeling to understand the impact of enzymes and transporters on drug and metabolite data and bioavailability estimates

Pharmaceutical Research

Volumn 27, Issue 7, 2010, Pages 1237-1254

  Sun, Huadong ^a,b   Pang, K Sandy ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b NoAb BioDiscoveries Inc   (Canada)

Author keywords

Area under the curve of metabolite; AUC ratios; Bioavailability; Drug disposition; Fraction absorbed; Metabolic enzymes; Metabolite kinetics; PBPK modeling; Transporters

Indexed keywords

DRUG METABOLITE; DRUG;

ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG TRANSPORT; INTESTINE; KIDNEY CLEARANCE; LIVER; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; PRIORITY JOURNAL; URINARY EXCRETION; BIOAVAILABILITY; BIOLOGICAL MODEL; ENZYMOLOGY; HUMAN; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; HUMANS; INTESTINES; LIVER; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS;

EID: 77953619214     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0049-2     Document Type: Article

References (54)

1. R Löbenberg GL Amidon 2000 Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards Eur J Pharm Biopharm 50 3 12 10.1016/S0939-6411(00)00091-6 10840189 (Pubitemid 30326685)
2. M Rowland 1972 Infuence of route of administration on drug bioavailability J Pharm Sci 61 70 4 10.1002/jps.2600610111 1:CAS:528: DyaE38XkvFyktg%3D%3D 5019220
3. JG Wagner 1972 An overview of the analysis and interpretation of bioavailability studies in man Pharmacology 8 102 17 10.1159/000136328 1:CAS:528:DyaE3sXpt1emtw%3D%3D 4644642
4. J Koch-Weser 1974 Bioavailability of drugs (first of two parts) N Engl J Med 291 233 7 1:STN:280:DyaE2c3mt1Wnug%3D%3D 4600408
5. J Koch-Weser 1974 Bioavailability of drugs (second of two parts) N Engl J Med 291 503 6 1:STN:280:DyaE2c3pvVOguw%3D%3D 4604153
6. S Riegelman M Rowland 1973 Effect of route of administration on drug disposition J Pharmacokinet Biopharm 1 419 34 10.1007/BF01059666 1:STN:280:DyaE2c7kt1Crtw%3D%3D 4787618
7. A Rescigno 2000 Area under the curve and bioavailability Pharmacol Res 42 539 40 10.1006/phrs.2000.0719 1:CAS:528:DC%2BD3MXhtlantg%3D%3D 11058405
8. G Cornaire J Woodley P Hermann A Cloarec C Arellano G Houin 2004 Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo Int J Pharm 278 119 31 10.1016/j.ijpharm.2004.03.001 1:CAS:528: DC%2BD2cXktFOiur4%3D 15158955 (Pubitemid 38670443)
9. E Batrakova S Lee S Li A Venne V Alakhov A Kabanov 1999 Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells Pharm Res 16 1373 9 10.1023/A:1018942823676 1:CAS:528:DyaK1MXmtVKktb4%3D 10496652 (Pubitemid 29449373)
10. T Minko EV Batrakova S Li Y Li RI Pakunlu VY Alakhov AV Kabanov 2005 Pluronic block copolymers alter apoptotic signal transduction of doxorubicin in drug-resistant cancer cells J Control Release 105 269 78 10.1016/j.jconrel.2005. 03.019 1:CAS:528:DC%2BD2MXlvVyrt7g%3D 15939500 (Pubitemid 40941992)
11. BM Johnson WN Charman CJ Porter 2002 An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E D-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine AAPS PharmSci 4 E40 10.1208/ps040440 12646011
12. AV Kabanov EV Batrakova VY Alakhov 2003 An essential relationship between ATP depletion and chemosensitizing activity of Pluronic block copolymers J Control Release 91 75 83 10.1016/S0168-3659(03)00211-6 1:CAS:528: DC%2BD3sXmsVSktb0%3D 12932639 (Pubitemid 37288878)
13. ED Hugger BL Novak PS Burton KL Audus RT Borchardt 2002 A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro J Pharm Sci 91 1991 2002 10.1002/jps.10176 1:CAS:528:DC%2BD38XmsVSgs7Y%3D 12210046 (Pubitemid 36254935)
14. Y Shono H Nishihara Y Matsuda S Furukawa N Okada T Fujita A Yamamoto 2004 Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes J Pharm Sci 93 877 85 10.1002/jps.20017 1:CAS:528:DC%2BD2cXivF2lsbo%3D 14999725 (Pubitemid 38420399)
15. H Zhang M Yao RA Morrison S Chong 2003 Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats Arch Pharm Res 26 768 72 10.1007/BF02976689 1:CAS:528:DC%2BD3sXotFKktro%3D 14560928
16. G Cornaire JF Woodley S Saivin JY Legendre S Decourt A Cloarec G Houin 2000 Effect of polyoxyl 35 castor oil and Polysorbate 80 on the intestinal absorption of digoxin in vitro Arzneimittelforschung 50 576 9 1:CAS:528:DC%2BD3cXkvFCnsL4%3D 10918954
17. V Risovic K Sachs-Barrable M Boyd KM Wasan 2004 Potential mechanisms by which Peceol increases the gastrointestinal absorption of amphotericin B Drug Dev Ind Pharm 30 767 74 10.1081/DDC-120039793 1:CAS:528:DC%2BD2cXmvVCltb4%3D 15491054 (Pubitemid 39311017)
18. ED Hugger KL Audus RT Borchardt 2002 Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers J Pharm Sci 91 1980 90 10.1002/jps.10175 1:CAS:528:DC%2BD38XmsVSgs7k%3D 12210045 (Pubitemid 36254934)
19. EM Collnot C Baldes MF Wempe J Hyatt L Navarro KJ Edgar UF Schaefer CM Lehr 2006 Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers J Control Release 111 35 40 10.1016/j.jconrel.2005.11.005 1:CAS:528:DC%2BD28XhslKjtL4%3D 16410030 (Pubitemid 43289992)
20. BD Rege JP Kao JE Polli 2002 Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers Eur J Pharm Sci 16 237 46 10.1016/S0928-0987(02)00055-6 1:CAS:528:DC%2BD38Xms1ynsro%3D 12208453
21. V Sancho-Chust S Fabra-Campos V Gomez-Meseguer M Bengochea A Martin-Villodre 1995 Experimental studies on the influence of surfactants on intestinal absorption of drugs. Cefadroxil as model drug and sodium lauryl sulfate as model surfactant: studies in rat colon Arzneimittelforschung 45 595 601 1:CAS:528:DyaK2MXmsVCqtrs%3D 7612059
22. IW Kim HJ Yoo IS Song YB Chung DC Moon SJ Chung CK Shim 2003 Effect of excipients on the stability and transport of recombinant human epidermal growth factor (rhEGF) across Caco-2 cell monolayers Arch Pharm Res 26 330 7 10.1007/BF02976964 1:CAS:528:DC%2BD3sXjvV2gsr8%3D 12735693
23. AF Kotze HL Luessen BJ de Leeuw BG de Boer JC Verhoef HE Junginger 1997 N-trimethyl chitosan chloride as a potential absorption enhancer across mucosal surfaces: in vitro evaluation in intestinal epithelial cells (Caco-2) Pharm Res 14 1197 202 10.1023/A:1012106907708 1:CAS:528:DyaK2sXmsFehurg%3D 9327448 (Pubitemid 27432543)
24. SM van der Merwe JC Verhoef JH Verheijden AF Kotze HE Junginger 2004 Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs Eur J Pharm Biopharm 58 225 35 10.1016/j.ejpb.2004.03. 023 15296951 (Pubitemid 39037231)
25. B Bittner RC Bravo González I Walter M Kappas J Huwyler 2004 Impact of Solutol HS 15 on the pharmacokinetic behaviour of colchicine upon intravenous administration to male Wistar rats Biopharm Drug Dispos 25 37 49 10.1002/bdd.383 14716751 (Pubitemid 38159262)
26. NF Smith MR Acharva N Desai WD Figg A Sparreboom 2005 Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel Cancer Biol Ther 4 815 8 1:CAS:528:DC%2BD28XkvVSnsLs%3D 16210916
27. RC Bravo González J Huwyler F Boess I Walter B Bittner 2004 In vitro investigation on the impact of the surface-active excipients Cremophor EL, Tween 80 and Solutol HS 15 on the metabolism of midazolam Biopharm Drug Dispos 25 37 49 10.1002/bdd.383 14716751 (Pubitemid 38159262)
28. X Ren X Mao L Si L Cao H Xiong J Qiu AD Schimmer G Li 2008 Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems after systemic administration Eur J Pharm Biopharm 70 279 288 10.1016/j.ejpb.2008.03.019 1:CAS:528:DC%2BD1cXhtVOitrnK 18499414
29. FDA Guidance for Industry. Bioavailability and bioequivalence studies for orally administered drug products-general considerations. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), March 2003.
30. SE Rosenblum J Lam 1997 Bioequivalence parameters of parent drug and its first-pass metabolite: comparative sensitivity to sources of pharmacokinetic variability Drug Dev Ind Pharm 23 237 344
31. AJ Jackson 2000 The role of metabolites in bioequivalency assessment. III. Highly variable drugs with linear kinetics and first pass effect Pharm Res 17 1432 6 10.1023/A:1007581016352 1:CAS:528:DC%2BD3MXlvFyltA%3D%3D 11205739 (Pubitemid 32109498)
32. Tucker G, Rostami A, Jackson P. Metabolite measurements in bioequivalence studies. Theoretical considerations. In: Midha KK, Blume HH, editors. Bio-International: bioavailability, bioequivalence and pharmacokinetics. Stuttgart: Medpharm Scientific Publishers; 1992. p. 163-70.
33. KK Midha MJ Rawson JW Hubbard 2004 Commentary. The role of metabolites in bioequivalence Pharm Res 21 1331 4 10.1023/B:PHAM.0000036906.65263.da 1:CAS:528:DC%2BD2cXmtlGnu7g%3D 15359567 (Pubitemid 39149647)
34. KS Pang ME Morris H Sun 2008 Formed and preformed metabolite: Facts and comparisons J Pharm Pharmacol 60 1247 75 10.1211/jpp.60.10.0001 1:CAS:528:DC%2BD1cXhtlWiurvN 18812018
35. M-L Chen AJ Jackson 1991 The role of metabolites in bioequivalency assessment. I. linear pharmacokinetics without first pass effect Pharm Res 8 25 32 10.1023/A:1015865920043 1:CAS:528:DyaK3MXhsFSjsb4%3D 2014204
36. M-L Chen AJ Jackson 1995 The role of metabolites in bioequivalency assessment. II. Drugs with linear pharmacokinetics and first-pass effect Pharm Res 12 700 8 10.1023/A:1016259509257 1:CAS:528:DyaK2MXlsFKls7k%3D 7479556
37. H Sun KS Pang 2009 Disparity in intestine disposition between formed and preformed metabolites and implications: A theoretical study Drug Metab Dispos 37 187 202 10.1124/dmd.108.022483 1:CAS:528:DC%2BD1MXhsVSlug%3D%3D 18948379
38. KS Pang 2003 Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series) Drug Metab Dispos 31 1507 19 10.1124/dmd.31.12.1507 1:CAS:528:DC%2BD3sXpt1KgsLo%3D 14625347 (Pubitemid 37466919)
39. KC Kwan 1997 Oral bioavailability and first-pass effects Drug Metab Dispos 25 1329 35 1:CAS:528:DyaK2sXotVymtr0%3D 9394021
40. S Yamazaki LN Toth E Kimoto J Bower J Skaptason D Romero TG Heath 2009 Application of stable isotope methodology in the evaluation of the pharmacokinetics of (S, S)-3-(3-(methylsulfonyl)phenyl)-1-propylpiperidine hydrochloride in rats Drug Metab Dispos 37 937 45 10.1124/dmd.108.025478 1:CAS:528:DC%2BD1MXlsVWitL0%3D 19237512
41. SA Peters 2008 Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles Clin Pharmacokinet 47 245 59 10.2165/00003088-200847040-00003 1:CAS:528:DC%2BD1cXltl2ntLk%3D 18336054 (Pubitemid 351367435)
42. KS Pang JR Gillette 1979 Sequential first-pass elimination of a metabolite derived from a precursor J Pharmacokinet Biopharm 7 275 90 10.1007/BF01060018 1:CAS:528:DyaE1MXmtVCisrk%3D 480149 (Pubitemid 9225442)
43. M Weiss 1988 A general model of metabolite kinetics following intravenous and oral administration of the parent drug Biopharm Drug Dispos 9 159 76 10.1002/bod.2510090205 1:CAS:528:DyaL1cXhsl2mt70%3D 3370305
44. M Weiss 1990 Use of metabolite AUC data in bioavailability studies to discriminate between absorption and first-pass extraction Clin Pharmacokinet 18 419 22 10.2165/00003088-199018050-00006 1:CAS:528:DyaK3cXkvFSrtrg%3D 2335047
45. B Davies T Morris 1993 Physiological parameters in laboratory animals and humans Pharm Res 10 1093 5 10.1023/A:1018943613122 1:STN:280: DyaK3szptFaqsg%3D%3D 8378254 (Pubitemid 23211439)
46. TM Dyke JA Hubbell RA Sams KW Hinchcliff 1998 Hepatic blood flow in horses during the recuperative period from maximal exercise Am J Vet Res 59 1476 80 1:STN:280:DyaK1M%2FksVyktw%3D%3D 9829410
47. A Shayeganpour DA Hamdy DR Brocks 2008 Pharmacokinetics of desethylamiodarone in the rat after its administration as the preformed metabolite, and after administration of amiodarone Biopharm Drug Dispos 29 159 66 10.1002/bdd.599 1:CAS:528:DC%2BD1cXmsVWnur8%3D 18161885 (Pubitemid 351722160)
48. M Peyrou A Bousquet-Melou V Laroute A Vrins MY Doucet 2006 Enrofloxacin and marbofloxacin in horses: comparison of pharmacokinetic parameters, use of urinary and metabolite data to estimate first-pass effect and absorbed fraction J Vet Pharmacol Ther 29 337 44 10.1111/j.1365-2885.2006.00752.x 1:CAS:528:DC%2BD28Xht1Wjtr%2FN 16958777 (Pubitemid 44337687)
49. PN Bennett LJ Aarons MR Bending JA Steiner M Rowland 1982 Pharmacokinetics of lidocaine and its deethylated metabolite: dose and time dependency studies in man J Pharmacokinet Biopharm 10 265 81 10.1007/BF01059261 1:CAS:528:DyaL3sXks1elug%3D%3D 7175699 (Pubitemid 12035887)
50. KT Lê H Maurice P du Souich 1996 First-pass metabolism of lidocaine in the anesthetized rabbit. Contribution of the small intestine Drug Metab Dispos 24 711 6 8818566
51. JP Hajda E Jähnchen S ∅ie D Trenk 2002 Sequential first-pass metabolism of nortilidine: the active metabolite of the synthetic opioid drug tilidine J Clin Pharmacol 42 1257 61 10.1177/009127002762491352 1:CAS:528:DC%2BD38XovVCltL4%3D 12412825 (Pubitemid 35205062)
52. MW Lo MR Goldberg JB McCrea H Lu CI Furtek TD Bjornsson 1995 Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans Clin Pharmacol Ther 58 641 9 10.1016/0009-9236(95)90020-9 1:CAS:528:DyaK28XhtVOgs7g%3D 8529329 (Pubitemid 26018849)
53. RL Lindberg EK Syvälahti 1986 Metabolism of nomifensine after oral and intravenous administration Clin Pharmacol Ther 39 378 83 1:CAS:528:DyaL28XitFymtLY%3D 3956054
54. RL Lindberg EK Syvälahti KK Pihlajamäki 1986 Disposition of nomifensine after acute and prolonged dosing Clin Pharmacol Ther 39 384 8 1:CAS:528:DyaL28XhvF2mtLw%3D 3956055